IL6 and cancer: Though catabolic drivers in the skeletal muscle of cachectic patients remain poorly characterized, IL‐6 is thought to contribute to human cancer wasting (Baracos et al, 2018) and elevated circulating IL‐6 has been shown to be increased in NSCLC patients and associated with reduced survival (Silva et al, 2017).